Clinical Trial Update: A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating venetoclax plus ibrutinib in T-cell prolymphocytic leukemia has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Leukemia, T-cell Prolymphocytic Leukemia (T-PLL) | Phase 2 | Status: COMPLETED | Results posted: 2022-12-19